FDA awards 18 grants to stimulate product development for rare diseases

21 September 2015 - The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more ...

Read more →

F.D.A. nominee Califf’s ties to drug makers worry some

20 September 2015 - At a DoubleTree Hotel in Durham, N.C., in May 2014, Dr. Robert M. Califf gave a presentation ...

Read more →

FDA approves new drug to treat schizophrenia and bipolar disorder

17 September 2015 - The U.S. Food and Drug Administration today approved Vraylar (cariprazine) capsules to treat schizophrenia and bipolar disorder ...

Read more →

FDA approves new indication for Spiriva Respimat

16 September 2015 - Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved Spiriva Respimat (tiotropium bromide ...

Read more →

Bristol-Myers Squibb’s Opdivo (nivolumab) receives breakthrough therapy designation from U.S. Food and Drug Administration for advanced renal cell carcinoma

16 September 2015 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy ...

Read more →

FDA approves Octapharma’s Nuwiq for the treatment of adults and children with haemophilia A

15 September 2015 - Octapharma USA today announced the U.S. Food and Drug Administration (FDA) has approved Nuwiq, anti-haemophilic factor (recombinant), ...

Read more →

AbbVie announces submission of a supplemental new drug application for Imbruvica (Ibrutinib) for treatment-naive chronic lymphocytic leukaemia

14 September 2015 - AbbVie, a global biopharmaceutical company, announced today that it submitted a supplemental New Drug Application (sNDA) to ...

Read more →

Erytech submits EMA marketing authorisation application for Graspa to treat acute lymphoblastic leukaemia

14 September 2015 - Erytech Pharma, the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other ...

Read more →

Amgen submits application to FDA for new delivery option for monthly administration of Repatha (evolocumab)

11 September 2015 - Amgen today announced the submission of an application to the U.S. Food and Drug Administration (FDA) seeking ...

Read more →

AbbVie's Humira (adalimumab) receives U.S. FDA approval for moderate to severe hidradenitis suppurativa

10 September 2015 - AbbVie, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Humira ...

Read more →

U.S. FDA accepts first digital medicine new drug application for Otsuka and Proteus Digital Health

10 September 2015 - Otsuka Pharmaceutical Co., Ltd. and Proteus Digital Health today announced that the United States Food and Drug ...

Read more →

FDA grants fast track designation for MediciNova's MN-001 (tipelukast) for the treatment of idiopathic pulmonary fibrosis

10 September 2015 - MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the ...

Read more →

U.S. FDA grants priority review to Takeda's ixazomib citrate for patients with relapsed/refractory multiple myeloma

9 September 2015 - Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has granted priority ...

Read more →

FDA grants Genentech’s alectinib priority review for specific type of ALK-positive lung cancer

9 September 2015 - Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) ...

Read more →

Alexion receives notification of PDUFA date extension for Kanuma (sebelipase alfa)

4 September 2015 - Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has extended the Prescription ...

Read more →